HENLIUS News

HENLIUS: VOLUNTARY ANNOUNCEMENT - FIRST PATIENT IN MAINLAND CHINA HAS BEEN DOSED IN AN INTERNATIONAL MULTI-CENTER PHASE 3 CLINICAL STUDY OF THE COMBINATION OF HLX78 (LASOFOXIFENE) AND ABEMACICLIB COMPARED TO THE COMBINATION OF FULVESTRANT AND ABEMACICLIB FOR THE TR

Dec 24 04:30 ET

HENLIUS: Disclosure of Dealings under Rule 22 of the Takeovers Code

Dec 24 00:13 ET

HENLIUS: POLL RESULTS OF THE RESOLUTION PROPOSED ATTHE 2024 FIRST EXTRAORDINARY GENERAL MEETINGHELD ON MONDAY, 23 DECEMBER 2024

Dec 23 05:18 ET

HENLIUS: Disclosure of Dealings under Rule 22 of the Takeovers Code

Dec 23 04:28 ET

HENLIUS: PROXY FORM FOR THE H SHAREHOLDERS' CLASS MEETING TO BE HELD ON 22 JANUARY 2025

Dec 22 05:59 ET

HENLIUS: PROXY FORM FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON 22 JANUARY 2025 (OR ANY ADJOURNMENT THEREOF)

Dec 22 05:57 ET

HENLIUS: NOTICE OF H SHAREHOLDERS' CLASS MEETING

Dec 22 05:55 ET

HENLIUS: NOTICE OF EXTRAORDINARY GENERAL MEETING

Dec 22 05:52 ET

HENLIUS: ELECTION FORM FOR THE CASH ALTERNATIVE OR THE SHARE ALTERNATIVE

Dec 22 05:49 ET

HENLIUS: (1) PROPOSED PRIVATISATION OF HENLIUS BY FOSUN NEW MEDICINE BY WAY OF MERGER BY ABSORPTION OF HENLIUS (2) PROPOSED WITHDRAWAL OF LISTING OF THE H SHARES OF HENLIUS (3) NOTICE OF THE EXTRAORDINARY GENERAL MEETING AND (4) NOTICE OF THE H SHAREHOLDERS' CLASS

Dec 22 05:46 ET

HENLIUS: JOINT ANNOUNCEMENT - DESPATCH OF COMPOSITE DOCUMENT IN RELATION TO THE PROPOSED PRIVATISATION OF HENLIUS BY FOSUN NEW MEDICINE BY WAY OF MERGER BY ABSORPTION OF HENLIUS

Dec 22 05:41 ET

HENLIUS: Disclosure of Dealings under Rule 22 of the Takeovers Code

Dec 20 03:48 ET

HENLIUS: INSIDE INFORMATION ANNOUNCEMENT - COLLABORATION AND LICENSE AGREEMENT WITH PALLEON FORE-602 AND COMBINATION THERAPY

Dec 19 05:30 ET

HENLIUS: Disclosure of Dealings under Rule 22 of the Takeovers Code

Dec 19 03:53 ET

HENLIUS: Disclosure of Dealings under Rule 22 of the Takeovers Code

Dec 18 04:54 ET

HENLIUS: JOINT ANNOUNCEMENT - FULFILMENT OF THE PRE-CONDITIONS OFTHE PROPOSED PRE-CONDITIONAL PRIVATISATIONOF HENLIUS BY FOSUN NEW MEDICINEBY WAY OF MERGER BY ABSORPTION OF HENLIUS

Dec 16 06:40 ET

HENLIUS: VOLUNTARY ANNOUNCEMENT - APPLICATION FOR THE PHASE 2 CLINICAL TRIAL OF HLX22(ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2 (HER2)HUMANISED MONOCLONAL ANTIBODY INJECTION)IN COMBINATION WITH TRASTUZUMABAND CHEMOTHERAPY OR HLX22 IN COMBINATIONWITH TRASTUZUMAB

Dec 4 05:08 ET

HENLIUS: VOLUNTARY ANNOUNCEMENT - APPLICATION FOR PHASE 1B/2 CLINICAL TRIAL OF HLX43FOR INJECTION (ANTIBODY-DRUG CONJUGATE TARGETINGPD-L1 WITH NOVEL DNA TOPOISOMERASE I INHIBITOR)FOR THE MONOTHERAPY OR COMBINATION THERAPYOF ADVANCE/METASTATIC SOLID TUMOURS WAS APPR

Dec 4 05:02 ET

HENLIUS: INSIDE INFORMATION ANNOUNCEMENT - NEW DRUG APPLICATION (NDA) FOR NEW INDICATION OFHANSIZHUANG (SERPLULIMAB INJECTION) IN COMBINATION WITHCHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF PATIENTSWITH LOCALLY ADVANCED OR METASTATIC NON-SQUAMOUSNON-SMALL CELL LUN

Dec 4 04:52 ET

HENLIUS: VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION (NDA) FOR PERTUZUMAB BIOSIMILARHLX11 (RECOMBINANT ANTI-HER2 DOMAIN II HUMANIZEDMONOCLONAL ANTIBODY INJECTION) HAS BEEN ACCEPTED BY THENATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA)

Dec 4 04:48 ET